We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genmab (GMAB) ADR SPON

Sell:$21.15 Buy:$21.16 Change: $0.47 (2.25%)
NASDAQ:0.60%
Market closed |  Prices as at close on 27 November 2024 | Switch to live prices |
Sell:$21.15
Buy:$21.16
Change: $0.47 (2.25%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 27 November 2024 | Switch to live prices |
Sell:$21.15
Buy:$21.16
Change: $0.47 (2.25%)
Market closed |  Prices as at close on 27 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact details

Address:
Carl Jacobsens Vej 30
VALBY
2500
Denmark
Telephone:
+45 () 70202728
Website:
https://www.genmab.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GMAB
ISIN:
US3723032062
Market cap:
$13.57 billion
Shares in issue:
63.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Denmark
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jan Van De Winkel
    President, Chief Executive Officer
  • Anthony Pagano
    Chief Financial Officer, Executive Vice President
  • Christopher Cozic
    Executive Vice President, Chief People Officer
  • Rayne Waller
    Executive Vice President, Chief Technology Officer
  • Tahamtan Ahmadi
    Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
  • Brad Bailey
    Executive Vice President and Chief Commercial Officer
  • Judith Klimovsky
    Executive Vice President, Chief Development Officer
  • Birgitte Stephensen
    Executive Vice President, Chief Legal Officer
  • Martine Van Vugt
    Executive Vice President, Chief Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.